289 related articles for article (PubMed ID: 34517192)
1. Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis.
Parks NE; Andreou P; Marrie RA; Fisk JD; Bhan V; Kirkland SA
Mult Scler Relat Disord; 2021 Nov; 56():103249. PubMed ID: 34517192
[TBL] [Abstract][Full Text] [Related]
2. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
[TBL] [Abstract][Full Text] [Related]
5. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
7. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
[TBL] [Abstract][Full Text] [Related]
8. Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC; Dobson R; Froud JLJ; St John FA; Anderson VM; Arun T; Buckley L; Evangelou N; Ford HL; Galea I; George S; Gray OM; Hibbert AM; Hu M; Hughes SE; Ingram G; Kalra S; Lim CE; Mathews JTM; McDonnell GV; Mescall N; Norris S; Ramsay SJ; Rice CM; Russell MJ; Shawe-Taylor MJ; Williams TE; Harding KE; Robertson NP
Eur J Neurol; 2024 Jul; 31(7):e16289. PubMed ID: 38567516
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
[TBL] [Abstract][Full Text] [Related]
10. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform.
Jokubaitis VG; Spelman T; Lechner-Scott J; Barnett M; Shaw C; Vucic S; Liew D; Butzkueven H; Slee M;
PLoS One; 2013; 8(3):e59694. PubMed ID: 23527252
[TBL] [Abstract][Full Text] [Related]
11. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
12. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
[TBL] [Abstract][Full Text] [Related]
13. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
15. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
[TBL] [Abstract][Full Text] [Related]
16. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
17. Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.
Melesse DY; Marrie RA; Blanchard JF; Yu BN; Evans C
Patient Prefer Adherence; 2017; 11():1093-1101. PubMed ID: 28721023
[TBL] [Abstract][Full Text] [Related]
18. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
19. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
[TBL] [Abstract][Full Text] [Related]
20. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.
Kozlicki MZ; Markley B; Shah NB; DeClercq J; Choi L; Zuckerman AD
Mult Scler Relat Disord; 2022 Jul; 63():103860. PubMed ID: 35609353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
